Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients

Contributions to Nephrology

Volumn 162, Issue , 2009, Pages 13-26

  Jordan, Stanley C ^a   Peng, Alice ^a   Vo, Ashley A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; RITUXIMAB;

BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; REVIEW; SPLENECTOMY;

ABO BLOOD-GROUP SYSTEM; ANTIBODIES, MONOCLONAL; BLOOD GROUP INCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; SPLENECTOMY;

EID: 59849100611     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000170864     Document Type: Article

References (62)

1. Evans RW, Manninen DL, Garrison LPJ, et al: The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-559.
2. Port FK, Wolfe RA, Mauger EA, et al: Comparison of survival probabilities for dialysis patients vs. cadaveric renal transplant recipients. JAMA 1993;270:1339-1343.
3. Russell JD, Beecroft ML, Ludwin D, Churchill DN: The quality of life in renal transplantation - a prospective study. Transplantation 1992;54:656-660.
4. Organ Procurement and Transplantation Network: Scientific registry of transplant recipients (accessed June 18, 2008, at http://www.optn.org/data/).
5. Kissmeyer-Nielsen F, Olsen S, Petersen V P, Fjeldborg O: Hyperacute rejection of kidney allo-grafts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966;ii: 662-665.
6. Patel R, Terasaki PI: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-739.
7. Williams GM, Hume DM, Hudson RPJ, Morris PJ, et al: 'Hyperacute' renal-homograft rejection in man. N Engl J Med 1968;279:611-618.
8. Starzl TE, Marchioro TL, Holmes JH, et al: Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964;55:195-200.
9. Gloor JM, DeGoey SR, Pineda AA, et al: Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003;3:1017-1023.
10. Gloor JM, Lager DJ, Moore SB, et al: ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003;75:971-977.
11. Montgomery RA, Cooper M, Kraus E, et al: Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transpl 2003;199-213.
12. Montgomery RA, Zachary AA, Racusen LC, et al: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887-895.
13. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al: A high panel-reactive antibody rescue protocol for crossmatch-positive live donor kidney transplants. Transplantation 2000;70:1531-1536.
14. Glotz D, Antoine C, Julia P, et al: Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 2004;17:1-8.
15. Glotz D, Antoine C, Julia P, et al: Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins. Am J Transplant 2002;2:758-760.
16. Glotz D, Haymann J P, Sansonetti N, et al: Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins. A potential tool for transplantation of immunized patients. Transplantation 1993;56:335-337.
17. Jordan SC, Vo A, Bunnapradist S, et al: Intravenous immune globulin treatment inhibits cross-match positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003;76:631-636.
18. Tyan DB, Li VA, Czer L, et al: Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994;57:553-562.
19. Alexandre G P, Squifflet J P, De Bruyere M, et al: Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987;19:4538-4542.
20. Alexandre G P, Squifflet J P, De Bruyere M, et al: Splenectomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant Proc 1985;17:138-143.
21. Tanabe K, Takahashi K, Sonda K, et al: Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998;65:224-228.
22. Breimer ME, Samuelsson BE: The specific distribution of glycolipid-based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation 1986;42:88-91.
23. Clausen H, Levery SB, Nudelman E, et al: Repetitive A epitope (type 3 chain A) defined by blood group A1-specific monoclonal antibody TH-1: chemical basis of qualitative A1 and A2 distinction. Proc Natl Acad Sci USA 1985;82:1199-1203.
24. Economidou J, Hughes-Jones NC, Gardner B: Quantitative measurements concerning A and B antigen sites. Vox Sang 1967;12:321-328.
25. Nelson P W, Helling TS, Pierce GE, et al: Successful transplantation of blood group A2 kidneys into non-A recipients. Transplantation 1988;45:316-319.
26. Sonnenday CJ, Warren DS, Cooper M, et al: Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004;4:1315-1322.
27. Tyden G, Kumlien G, Fehrman I: Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003;76: 730-731.
28. Warren DS, Zachary AA, Sonnenday CJ, et al: Successful renal transplantation across simultaneous ABO-incompatible and positive crossmatch barriers. Am J Transplant 2004;4:561-568.
29. Jordan SC, Cunningham-Rundles C, McEwan R: Utility of IVIG in kidney transplantation. Am J Transplant 2003:3:653-664.
30. Tyan DB, Li VA, Czer L, et al: Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994;57:553-562.
31. Jordan SC, Quartel AW, Czer LS, et al: Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998;66:800-805.
32. Jordan SC, Vo A, Bunnapradist S, et al: Intravenous gammaglobulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003;76:631-636.
33. Jordan SC, Tyan D, Stablein D, et al: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly HLA-sensitized adult patients with end-stage renal disease: report of the NIH-IGO2 trial. J Am Soc Nephrol 2004;15:3256-3262.
34. Jordan SC, Vo A, Peng A, et al: Intravenous gammaglobulin: a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006;6:459-466.
35. Jordan SC, Pescovits M: Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006;1:421-432.
36. Jordan SC, Tyan DB: Intravenous gammaglobulin inhibits lymphocytotoxic antibody in vitro. J Am Soc Nephrol 1991;2:803.
37. Peng A, Vo A, Villicana R, et al: Long-term graft and patient outcomes in highly HLA-sensitized deceased donor kidney transplant recipients desensitized with high dose IVIG. Am J Transplant 2008;8:303.
38. Montgomery RA, Zachary AA: Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004;8:535-542.
39. Vo A, Lukovsky M, Toyoda M, et al: Rituximab and intravenous immune globulin for desensitiza-tion during renal transplantation. N Engl J Med 2008;359:242-251.
40. Vo A, Lukovsky M, Toyoda M, et al: Safety and adverse event profiles of IVIG products used for immunomodulation a single-center experience. Clin J Am Soc Nephrol 2006;1:844-152.
41. Coghill J, Comeau T, Shea T, et al: Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin. Biol Blood Marrow Transplant 2006;12:786-788.
42. Kaplan B, Gangemi A, Thielke J, et al: Successful rescue of refractory, severe antibody-mediated rejection with splenectomy. Transplantation 2007;83:99-100.
43. Locke JE, Zachary AA, Haas M, et al: The utility of splenectomy as rescue treatment for severe acute antibody-mediated rejection. Am J Transplant 2007;7:842-846.
44. Gentry SE, Segev DL, Montgomery RA: A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant 2005;5:1914-1921.
45. Segev DL, Gentry SE, Warren DS, et al: Kidney paired donation and optimizing the use of live donor organs. JAMA 2005;293:1883-1890.
46. Locke JE, Gentry SE, Simpkins CE, et al: Combining kidney paired donation, desensitization, and non-directed donors to transplant multiple highly sensitized patients. Am J Transplant 2006;6:808.
47. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
48. Sameulsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;29:484-486.
49. Magee JC, Collins BH, Harland RC, et al: Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995;96:2404-2412.
50. Lutz HU, Stammler P, Bianchi V, et al: Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004;103:465-472.
51. Toyoda M, Pao A, Petrosian A, Jordan SC: Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003;3:156-166.
52. Kaneko Y, Nimmerjahn F, Madaio M, Ravetch J: Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006;203:789-797.
53. Anthony RM, Nimmerjahn F, Ashline DJ, et al: Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008;320:373-376.
54. Li N, Zhao M, Hilario-Vargas J, et al: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005;115:3440-3450.
55. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al: Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003;101:758-765.
56. Gill V, Doig C, Knight D, et al: Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005;112:2031-2039.
57. Turhan A, Jenab P, Bruhns P, et al: Intravenous gammaglobulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 2004;103:2397-2400.
58. Park-Min KH, Serbina NV, Yang W, et al: FcγRIII-dependent inhibition of interferon-γ responses mediates suppressive effects of intravenous immune globulin. Immunity 2007;26:67-78.
59. Kessel A, Ammuri H, Peri R, et al: Intravenous immunoglobulin therapy affects T-regulatory cells by increasing their suppressive function. J Immunol 2007;179:5571-5575.
60. Stasi R, Cooper N, Del Poeta G, et al: Analysis of regulatory T-cell changes in patients with ITP receiving B-cell depleting therapy with rituximab. Blood 2008;112:1147-1150.
61. De Groot A, Moise L, McMurry J, et al: Activation of natural regulatory T-cells by IgG Fc-derived peptide 'tregitopes'. Blood 2008 (in press).
62. Abe J, Jibiki T, Noma S, et al: Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005;174:5837-5845.